AAV Empty Capsid Drug Loading via Controlled Heating
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for using AAV-derived empty capsids as drug delivery carriers face challenges in maintaining early infection activities and efficiently introducing drugs without viral growth activities, leading to safety and efficacy issues.
Innovation Solution
A method involving heating a culture solution of helper virus-uninfected host cells to coagulate proteins, followed by centrifugation or filtration, and using surfactants to introduce drugs into empty capsids, while removing surfactants post-introduction, to create a drug delivery particle with preserved early infection activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional methods (urea, heat, or pH conditions) are used to denature empty capsids for drug introduction, then drugs can be introduced into capsids, but the capsids lose their early infection activities and can no longer function as delivery carriers
Solution Approach 1:
The patent applies parameter changes by heating the capsid-drug mixture to a specific temperature range (40-60°C) for a controlled duration (5-30 minutes). This thermal treatment facilitates drug penetration into the capsid while preserving the capsid's structural integrity and early infection activities, resolving the contradiction between drug introduction capability and functional reliability
Solution Approach 2:
The patent uses partial action by applying mild heating (40-60°C) rather than extreme denaturation conditions. This moderate thermal treatment is sufficient for drug introduction but does not cause complete capsid denaturation, thereby maintaining both drug delivery capability and infectious functionality
2Object-affected harmful factors
If empty capsids are used as drug delivery carriers to avoid viral growth activities, then safety is improved, but the technique for introducing drugs while preserving early infection activities has not been established
Solution Approach 1:
The patent uses heat as an intermediary mechanism to facilitate drug introduction into empty capsids. By applying controlled thermal energy (40-60°C for 5-30 minutes), the capsid membrane becomes more permeable to drugs without causing denaturation, thus enabling drug loading while maintaining capsid functionality and safety
3Manufacturing precision
If heating is applied to coagulate proteins for purification, then impurities are removed, but excessive heating may damage the empty capsids and reduce early infection activities
Solution Approach 1:
The patent optimizes heating parameters to a specific temperature range (40-60°C) and time duration (5-30 minutes) that is sufficient for protein coagulation and capsid purification but does not exceed the threshold for capsid damage. This controlled thermal treatment achieves effective impurity removal while preserving capsid integrity and early infection activities
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method efficiently purifies AAV-derived empty capsids, allows for target cell-specific drug delivery, and enhances safety by avoiding viral growth activities, resulting in a high-yield, effective drug delivery system.
Implementation Method 1
the step of heating a culture solution of a helper virus-uninfected host cell and/or an extract of the host cell that has produced the AAV-derived empty capsid, or the virion thereof, and the step of removing the coagulated proteins from the culture solution and/or the extract after the heating step by centrifugation or filtration
Implementation Method 2
removing the coagulated proteins from the culture solution and/or the extract after the heating step by centrifugation or filtration
Implementation Method 3
removing the coagulated proteins from the culture solution and/or the extract after the heating step by centrifugation or filtration
Data Source
Figure 1
Figure 2
Figure 3A~3E
AI summary
An object of the present invention is to develop and provide a method for conveniently introducing a nucleic acid, a peptide, and/or a low-molecular-weight compound into an empty capsid with viral early infection activities kept. The present invention provides a method for producing a drug delivery particle, comprising the steps of: mixing an empty capsid or an empty particle with a drug including a nucleic acid, a peptide, and/or a low-molecular-weight compound in a solution comprising 0.1 to 20% of a surfactant; and keeping the obtained mixed solution at -5 to 50°C to introduce the drug into the empty capsid or the empty particle.